SEARCH:   Advanced

Blood, 15 January 2005, Vol. 105, No. 2, pp. 545-547. Prepublished online as a Blood First Edition Paper on September 28, 2004; DOI 10.1182/blood-2004-01-0322. This Article Full Text (PDF) All Versions of this Article: 2004-01-0322v1 105/2/545    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bakanay, S. M Articles by Kutlar, A. Search for Related Content PubMed PubMed Citation Articles by Bakanay, S. M Articles by Kutlar, A. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 28, 2004 Accepted September 1, 2004 Mortality in Sickle Cell Patients on Hydroxyurea Therapy Sule M Bakanay, Erin Dainer, Betsy Clair, Adekunle Adekile, Lisa Daitch, Leigh Wells, Leslie Holley, David Smith, and Abdullah Kutlar* Sickle Cell Center, Department of Medicine, Medical College of Georgia, Augusta, GA, USA Office of Biostatistics & Bioinformatics, Medical College of Georgia, Augusta, GA, USA * Corresponding author; email: akutlar{at}mcg.edu. The efficacy of hydroxyurea (HU) and its role in the reduction in mortality in sickle cell patients has been established. However many patients still die from complications of this disease while on HU. Of the 226 patients treated with HU at our center, 38 died (34 of sickle cell-related causes). Acute chest syndrome (ACS) was the most common cause of death (35%). The deceased and surviving patients did not differ significantly in average HU dose, baseline Hb F, or maximum Hb F response. However, the deceased patients were significantly older when HU was instituted, were more anemic and more likely to have BAN or CAM haplotypes. They also had significantly higher serum BUN and creatinine. Sickle cell patients who die whilst on HU therapy may represent a subgroup of older patients, possibly with more severe disease and organ damage. Such patients need early identification and prompt HU institution. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Sickle cell disease and hydroxyurea: the good, the bad, and the future Martin H. Steinberg Blood 2005 105: 441. [Full Text] [PDF] This article has been cited by other articles: I. Berthaut, G. Guignedoux, F. Kirsch-Noir, V. de Larouziere, C. Ravel, D. Bachir, F. Galacteros, P.-Y. Ancel, J.-M. Kunstmann, L. Levy, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males Haematologica, July 1, 2008; 93(7): 988 - 993. [Abstract] [Full Text] [PDF] B. C. McClain and Z. N. Kain Pediatric Palliative Care: A Novel Approach to Children With Sickle Cell Disease Pediatrics, March 1, 2007; 119(3): 612 - 614. [Full Text] [PDF] G. R. Buchanan and M. J. Kahn Hemolytic anemias ASH Self-Assessment Program, January 1, 2007; 2007(1): 102 - 142. [Full Text] [PDF] A. D. Villella Mortality in Sickle Cell Patients on Hydroxyurea Therapy AAP Grand Rounds, August 1, 2005; 14(2): 14 - 15. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020